Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of the efficacy of isatuximab, pomalidomide, and dexamethasone in patients with multiple myeloma refractory to daratumumab finds median PFS of 5.8 months (12-month PFS 30.6%); Hb <11.8 g/L predicted 3.5x increased risk of progression, high risk FISH was 10x.”

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

Authors: Enrica Antonia Martino et al.

Myeloma Paper of the Day, February 4th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.